NCBI PubMed Central
open access
Atogepant reduces triptan use: a pharmacoeconomic analysis in migraine prevention.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Efficacy and safety of gepants in migraine management: a narrative review focusing on atogepant and rimegepant#1000632
- Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine#871658
- Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications#890915
- The Lacosamide's Effect on Calcitonin Gene-related Peptide in Migraine Patients#1086764
- Headache Provocation of People Who Are Unable to Have Headache#1033503
Record · ID 312477
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive